A breakthrough medicine is only useful if it reaches the right patient at the right time.
McKesson reports Wednesday after the close, giving investors a fresh test of pharmaceutical distribution, oncology demand, specialty-drug services, prescription technology, and the cash flow generated behind the healthcare system.
AI shift (Sponsored)
Artificial intelligence is changing the way companies operate—and one new initiative linked to Elon Musk is attracting attention.
According to a veteran market analyst, the biggest opportunity may not be the household names, but a little-known company supporting the technology behind the scenes.
His free briefing reveals the trend and the stocks he's watching.
Watch the Free Briefing
Theme: Specialty Distribution, Oncology Networks, Pharmacy Benefits, Home Infusion, and Drug Access
Modern Drugs Need More Support
The pharmaceutical supply chain used to look relatively straightforward.
A manufacturer produced a drug. A wholesaler delivered it to a pharmacy or hospital. A patient received the prescription.
Specialty medicines make that process much more complicated.
Many oncology drugs, biologics, immune therapies, and injectable treatments require temperature-controlled shipping, prior authorization, reimbursement support, clinical monitoring, and carefully managed inventory.
The medicine may also need to be administered in a physician’s office, infusion center, or patient’s home.
Complexity Creates Value
That complexity creates opportunities beyond basic distribution.
Drug companies need help getting treatments approved and reimbursed. Physicians need inventory and clinical support. Insurers and pharmacy-benefit managers need to manage rapidly rising costs. Patients need assistance navigating coverage and treatment.
The companies that control more of this infrastructure can earn revenue from logistics, technology, specialty pharmacies, provider networks, and patient services.
The margins on simple distribution remain thin. The economics improve as companies move deeper into the services surrounding the drug.
What’s Driving It
McKesson Is the After-Close Catalyst
McKesson releases its fiscal first-quarter results after Wednesday’s market close, followed by its earnings call at 4:30 p.m. ET. That keeps the catalyst ahead of readers rather than relying on information released earlier in the morning.
The company enters the report after a strong fiscal year.
Fiscal 2026 revenue increased 12% to $403.4 billion. Adjusted EPS rose 18% to $39.11, while free cash flow reached $5.4 billion.
McKesson returned $5.1 billion to shareholders and established fiscal 2027 adjusted EPS guidance of $43.80 to $44.60, representing expected growth of 12% to 14%.
The Portfolio Is Moving Toward Specialty Care
McKesson is investing heavily in oncology, multispecialty practices, and services that help pharmaceutical companies connect patients with treatments.
Its longer-term targets call for adjusted operating-profit growth of 13% to 16% in Oncology & Multispecialty and 10% to 13% in Prescription Technology Solutions.
The company is also separating its lower-growth Medical-Surgical business and has exited its European operations. The goal is a more focused portfolio with a larger contribution from higher-growth, higher-margin services.
Cardinal Health Has Strong Earnings Momentum
Cardinal Health reported fiscal third-quarter revenue of $60.9 billion, up 11%.
Non-GAAP operating earnings increased 18%, while adjusted EPS rose 35% to $3.17. Management raised and narrowed its fiscal-year adjusted EPS outlook to between $10.70 and $10.80.
The company also completed $1 billion of fiscal-year share repurchases through the quarter.
Pharmacy Services Are Still Growing
Cigna reported second-quarter revenue of $71.7 billion, up 7%, while adjusted EPS increased to $7.78.
The company raised its full-year adjusted EPS outlook to at least $30.45. Growth across Evernorth’s pharmacy and specialty-care operations helped support the results.
Elevance Health reported second-quarter operating revenue of $49.8 billion.
Carelon revenue increased 6% to $19.2 billion, supported by growth in CarelonRx product revenue and risk-based healthcare services. Carelon’s operating gain rose 1%, helped by improved specialty-pharmacy profitability.
Treatment Is Moving Into the Home
Option Care Health provides another layer of the specialty-drug system.
Second-quarter revenue increased 1.9% to $1.44 billion. Adjusted EBITDA rose 3% to $117.5 million, while adjusted EPS increased 9.8% to $0.45.
The company generated $184 million of operating cash flow during the quarter and repurchased $150 million of stock.
Here is the chain reaction:
Specialty-drug volumes rise → distribution demand increases
Treatments become more complex → support services gain value
Provider networks expand → more care moves outside hospitals
Pharmacy platforms gain scale → recurring revenue strengthens
Policy or reimbursement changes → margins come under pressure
What’s Working
The strongest growth is coming from medicines used to treat cancer, autoimmune diseases, rare conditions, and other complex illnesses.
These products often generate more revenue per prescription than traditional drugs. They also require more support from distributors, pharmacies, providers, and insurers.
That creates opportunities for McKesson, Cardinal Health, Cigna, and Elevance to earn revenue beyond the initial delivery.
Community Oncology Is Expanding
More cancer treatment is moving into community practices rather than large hospital systems.
McKesson supports these practices through The US Oncology Network and its specialty-distribution platform. The model connects physicians with drugs, clinical tools, administrative services, and purchasing scale.
The company can therefore participate in both the distribution of the medicine and the infrastructure used to administer it.
Patient Access Is Becoming a Business
A treatment may be approved and prescribed but still fail to reach the patient.
Insurance verification, prior authorization, copay assistance, pharmacy selection, and reimbursement delays can all interrupt care.
McKesson’s Prescription Technology Solutions business helps manufacturers and providers navigate those steps. Cigna and Elevance approach the problem through pharmacy benefits and specialty-pharmacy services.
The companies that simplify access can create value for manufacturers, providers, and patients at the same time.
Home Infusion Can Lower Costs
Some therapies that once required a hospital visit can now be delivered in an infusion center or a patient’s home.
Option Care Health provides nursing, pharmacy, logistics, and clinical support across that process.
The model can reduce costs for insurers while making treatment more convenient for patients. It also creates recurring relationships because many therapies require multiple infusions over long periods.
McKesson (MCK)
What it does:
McKesson distributes pharmaceuticals and provides oncology services, prescription technology, specialty-drug support, and healthcare infrastructure.
Why it fits:
McKesson is the direct after-close earnings catalyst and the quality anchor in the basket.
Its fiscal 2026 revenue rose 12%, adjusted EPS increased 18%, and free cash flow reached $5.4 billion.
What stands out:
This is the specialty-services compounder.
McKesson is moving deeper into oncology practices, patient access, specialty distribution, and biopharma services. These businesses offer better growth and stronger margins than basic wholesale distribution.
The company is also simplifying its portfolio while aggressively returning capital.
What to watch:
Watch North American Pharmaceutical growth, Oncology & Multispecialty profit, Prescription Technology Solutions, free cash flow, share repurchases, and fiscal 2027 guidance.
The Takeaway: Buy this first if you want the strongest direct catalyst and highest-quality specialty distribution platform.
The risk is that low-margin drug volumes grow faster than the higher-margin services surrounding them.
Cardinal Health (CAH)
What it does:
Cardinal Health distributes pharmaceuticals and medical products while operating specialty, home-care, logistics, and provider-support businesses.
Why it fits:
Cardinal gives the basket strong current earnings momentum.
Its latest quarter produced 11% revenue growth, 18% adjusted operating-earnings growth, and a 35% increase in adjusted EPS.
What stands out:
This is the improving-mix distributor.
Cardinal is expanding in specialty pharmaceuticals, at-home care, nuclear pharmacy, and provider-management services. These businesses can reduce dependence on traditional distribution volume.
The company is also producing enough cash to reduce debt and repurchase shares.
What to watch:
Watch Pharmaceutical and Specialty Solutions profit, specialty volumes, medical-product margins, tariffs, free cash flow, and the August 11 earnings report.
The Takeaway: Buy this if you want a distributor with strong earnings momentum and expanding specialty exposure.
The risk is that pressure in medical products offsets gains in pharmaceutical distribution.
Learn More (Sponsored)
A $7.2 trillion financial shift is already underway.
Dr. David Eifrig calls it the “Mar-a-Lago Trade,” and he believes it could create one of the biggest retirement opportunities of the year.
It has nothing to do with AI, risky IPOs, or crypto.
Instead, it is tied to a major policy move already being discussed in Washington, one that Bloomberg says could trigger a “dire shift of fortunes for America.”
Dr. Eifrig says investors who understand it early could have a rare chance to prepare before this story spreads.
The Cigna Group (CI)
What it does:
Cigna operates employer health plans, pharmacy-benefit services, specialty pharmacy, care-management tools, and healthcare services through Cigna Healthcare and Evernorth.
Why it fits:
Cigna gives the basket a large pharmacy-benefit and specialty-care platform.
Second-quarter revenue increased 7%, adjusted EPS reached $7.78, and management raised its 2026 outlook.
What stands out:
This is the pharmacy-services cash-flow stock.
Evernorth handles drug benefits, specialty pharmacy, care solutions, and employer services. That creates recurring contracts and purchasing scale across a large member base.
Cigna also has less dependence on government-backed insurance than several managed-care peers.
What to watch:
Watch Evernorth revenue, specialty-pharmacy growth, client retention, pharmacy-benefit margins, cash flow, and capital returns.
The Takeaway: Buy this if you want a large pharmacy-services platform with strong recent execution.
The risk is regulatory pressure on pharmacy-benefit managers and their rebate economics.
Elevance Health (ELV)
What it does:
Elevance operates health plans and provides pharmacy, behavioral, clinical, home-health, and complex-care services through Carelon.
Why it fits:
Elevance gives the basket another pharmacy-services platform with a broader insurance base.
Carelon revenue rose 6% to $19.2 billion in the second quarter, supported by CarelonRx and risk-based health services.
What stands out:
This is the integrated-care recovery.
Carelon allows Elevance to earn revenue from pharmacy services, specialty care, behavioral health, and other clinical programs beyond the insurance premium.
Improved specialty-pharmacy profitability helped support Carelon’s latest-quarter results.
What to watch:
Watch CarelonRx revenue, specialty-pharmacy profitability, medical costs, member retention, operating cash flow, and guidance.
The Takeaway: Buy this if you want pharmacy-services growth with additional upside from improving insurance operations.
The risk is that elevated medical costs absorb the gains coming from Carelon.
The Wealth Strategy (Sponsored)
His official salary? $400,000 a year.
Yet his returns point to something far bigger: Up to $250,000 per month… from just one place.
It’s not property. It’s not equities.
So what’s really generating this kind of income — and why is it gaining traction now?
Which structural shift do you think will generate the most investment returns over the next decade?
Option Care Health (OPCH)
What it does:
Option Care Health provides home and alternate-site infusion therapy, specialty pharmacy, nursing, clinical monitoring, and medication-delivery services.
Why it fits:
Option Care gives the basket direct exposure to treatments moving out of hospitals.
Second-quarter adjusted EPS rose 9.8%, while the company generated $184 million of operating cash flow.
What stands out:
This is the home-infusion specialist.
Option Care can help insurers reduce treatment costs while giving patients a more convenient setting for long-term therapy.
Its national clinical and pharmacy network is difficult to replicate, and many treatments create recurring demand.
What to watch:
Watch revenue growth, therapy mix, gross margin, adjusted EBITDA, operating cash flow, reimbursement, and patient volumes.
The Takeaway: Buy this if you want the most focused play on specialty treatment moving into the home.
The risk is that reimbursement pressure and unfavorable drug mix hold revenue growth above profit growth.
Elite Trade Club Insider
One Director Sold Into a 58% Surge. Two Defense Executives Moved $36 Million.
One insider cashed out more than $2 million after his stock gained nearly 480% in a year and 58% in five sessions.
Elsewhere, two executives reported more than $36 million in sales near a 52-week high. But the option exercises underneath those transactions completely change the signal, and Insider readers are seeing which sale deserves the real caution.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE SQUEEZE
The defensive sleeve: staples and steady compounders, boring on purpose, built for the nights you'd rather sleep than watch futures.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
